Chairman of the Board of Directors
Board of Directors
symphogen
Denmark
Dr. Ando was CEO of Celltech Group plc, UK, until 2004. He joined Celltech from Pharmacia, now Pfizer, where he was Executive Vice President and President of R&D with additional responsibilities for manufacturing, IT, business development and Mergers & Acquisitions from 1995 to 2003. From 1989 to 1995, Dr. Ando was Medical Director, moving to Deputy R&D Director and then R&D Director of Glaxo Group, UK. He was also a member of the Glaxo Group Executive Committee. Dr. Ando serves as Chairman of Novo Nordisk A/S, and as board member of Novo Holdings A/S, Molecular Partners AG, and EUSA Pharma and ICMEC (International Centre for Missing and Exploited Children). He also serves as a Senior Advisor to Essex Woodlands Health Ventures UK Ltd. Dr. Ando is a Specialist in General Medicine and is a Founding Fellow of the American College of Rheumatology in the U.S. Dr. Ando serves as Chairman of Symphogen's Remuneration Committee
General Medicine